Results Associative learning activates MAPK To investigate the role of the MAPK cascade in mammalian learning, we determined if learning is associated with activation of MAPK.

A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional protein that has been associated with the ...

The ProTac HL® 6 tactical light from Streamlight delivers up to 5,300 lumens. EAGLEVILLE, PA, July 1, 2024 - Streamlight® Inc., a leading provider of high-performance lighting and weapon light ...

Researchers have developed an improved type of PROTAC that has enhanced intracellular accumulation and functions, not only as a degrader, but also as an inhibitor of the target protein.

The PROTAC market is anticipated to expand considerably in the near future, driven by the rising number of PROTAC-based drugs undergoing clinical trials from multiple companies. At present, no ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy ...

The PROTAC candidates “… demonstrate potent antiretroviral activity in HIV-infected primary cells, supporting further development for testing in the context of HIV-1 reservoir reduction in ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

Genentech, a division of Roche, will pay China’s Jemincare $60 million up front in a deal to develop a prostate cancer treatment that is based on targeted protein degradation. Proteolysis ...

Son of sevenless homolog 1 (SOS1) is an essential guanine nucleotide exchange factor (GEF) in KRAS-driven tumors, and it also functions as a downstream node protein of BCR-ABL, suggesting its critical ...